We have recently shown that TYK2 suppresses the expression of indolamine 2-3-deoxygenase 1 (Ido-1) in cancer cells, thereby promoting anti-cancer immunity of autochthonous colitis-associated CRC (12). Here, TYK2 is linked to colorectal carcinoma.